Premium functions are now FREE OF CHARGE due to the modification of the investment data Data developments may cause some parts work incorrectly Incorrect sections - Financial statements, Earnings upcoming dates and calendars Please take our apologise. It will be fixed soon

SLRX - Salarius Pharmaceuticals Inc


Previous close
1.72
0   0%

Share volume: 30,335
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.72
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 8%
Dept financing 3%
Liquidity 58%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-10.75%
1 Month
-49.70%
3 Months
-55.04%
6 Months
-67.98%
1 Year
-76.15%
2 Year
-95.97%
Key data
Stock price
$1.72
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.35 - $7.60
52 WEEK CHANGE
-$0.77
MARKET CAP 
2.392 M
YIELD 
N/A
SHARES OUTSTANDING 
1.441 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$113,911
AVERAGE 30 VOLUME 
$1,036,811
Company detail
CEO: David Arthur
Region: US
Website: http://www.flex-pharma.com/
Employees: 14
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

salarius is an oncology based biotechnology company developing targeted treatments for patients who need them the most.

Recent news